All In Biotech

Drug Trial Radar · NCT07842185

A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke

A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke(INSTANT-2)

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,192 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,192

Planned (sponsor's estimate)

Start

Dec 19, 2026

Primary completion

Dec 30, 2030

Study completion May 8, 2031

Sponsor

Lead sponsor
Xinqiao Hospital of ChongqingAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Affiliated Ganzhou Hospital of Nanchang University
First posted
Sep 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute ischemic stroke is a leading cause of disability and mortality among dults in China. Although intravenous thrombolysis serves as first-line reperfusion therapy, nearly half of patients fail to achieve vascular recanalization. The reocclusion rate ranges from 14% to 34%, and many patients are left with residual neurological deficits. Early antiplatelet therapy initiated after thrombolysis may sustain persistent reperfusion and improve prognosis. However, current guidelines generally recommend delaying antiplatelet treatment until 24 hours post-thrombolysis due to bleeding risks, and direct evidence for the optimal initiation timing remains lacking. Tirofiban is a rapidly acting, short-half-life, reversible glycoprotein IIb/IIIa receptor antagonist. Previous studies indicate its potential benefits and acceptable safety when administered after intravenous thrombolysis. This is a multicenter, open-label, endpoint-blinded randomized controlled trial. A total of 1192 non-cardioembolic patients without large or medium vessel occlusion and with residual neurological deficits (NIHSS ≥4) after thrombolysis will be enrolled. Participants will be randomly allocated to the tirofiban 24-hour group, tirofiban 48-hour group. The primary outcome is the proportion of patients with excellent functional outcome defined as modified Rankin Scale (mRS) score 0-1 at 90 days. Symptomatic intracranial hemorrhage and neurological outcomes will also be evaluated. The study aims to determine the optimal duration of tirofiban treatment after thrombolysis and provide high-level evidence for precise interventions in the acute phase of stroke.

Conditions

  • Acute Ischemic Stroke

Interventions

  • Tirofiban InjectionDrug

    Intravenous infusion of tirofiban will be initiated after intravenous thrombolysis and continued for 24 hours. The dosage regimen follows the trial protocol.

  • Tirofiban InjectionDrug

    Intravenous infusion of tirofiban will be initiated after intravenous thrombolysis and continued for 48 hours. The dosage regimen follows the trial protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with mRS 0-1 at 90 daysTime frame: 90 days after randomization

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Taihe County People's Hospital

    Fuyang, Anhui, China

  • Longyan First Hospital of Fujian Medical University

    Longyan, Fujian, China

  • Xiangtan Central Hospital (The Affiliated Hospital of Hunan University)

    Xiangtan, Hunan, China

  • Ganzhou People's Hospital

    Ganzhou, Jiangxi, China

  • Xingguo People's Hospital, Xinguo Hospital of Gannan Medical University

    Ganzhou, Jiangxi, China

  • Jingdezhen First People's Hospital

    Jingdezhen, Jiangxi, China

  • The First People's Hospital of Jingdezhen City

    Jingdezhen, Jiangxi, China

  • Jiujiang First People's Hospital

    Jiujiang, Jiangxi, China

  • Dalian Central Hospital

    Dalian, Liaoning, China

  • The First People's Hospital of Mianyang (Mianyang 404 Hospital)

    Mianyang, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.